Since 1995, both clinical trials and meta-analyses have shown that the addition of platinum-based chemotherapy leads to a mere 5% increase in 5-year OS in NSCLC patients with diseases at stagesIB, II, and IIIA.221 Currently, for stageIB-IIIA patients with sensitive EGFR mutations (Ex19 del or L858R), based on the ADAURA trial outcomes,222 three years of osimertinib adjuvant therapy is recommended, regardless of PD-L1 status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.